Results 201 to 210 of about 7,956,506 (236)
Some of the next articles are maybe not open access.

Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group.

Archives of ophthalmology (Chicago, Ill. : 1960), 1993
The purpose of the present study was to determine the baseline visual field characteristics in 448 patients with acute optic neuritis who were entered into the Optic Neuritis Treatment Trial. The severity and pattern of visual field loss in both the affected and fellow eyes were classified. For affected eyes, diffuse visual field loss was present in 48.
J L, Keltner   +3 more
openaire   +1 more source

The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group.

Archives of ophthalmology (Chicago, Ill. : 1960), 1992
The baseline characteristics of 448 eligible patients entered into the Optic Neuritis Treatment Trial are described in an effort to summarize the clinical profile of acute optic neuritis. A total of 77.2% of the patients were women. Mean age was 31.8 years. Pain accompanied the visual loss in 92.2% of cases.
openaire   +1 more source

Prepublication Blackout in the Optic Neuritis Treatment Trial-Reply

Archives of Ophthalmology, 1994
In reply We appreciate having the opportunity to respond to the thoughtful comments of Drs Slavin and Burde. As will be evident from our discussion below, dissemination of our results in a timely and appropriate manner was given considerable deliberation by the study investigators as well as the National Eye Institute (NEI), which funded the ONTT.
openaire   +1 more source

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

The New England journal of medicine, 1992
The use of corticosteroids to treat optic neuritis is controversial. At 15 clinical centers, we randomly assigned 457 patients with acute optic neuritis to receive oral prednisone (1 mg per kilogram of body weight per day) for 14 days; intravenous methylprednisolone (1 g per day) for 3 days, followed by oral prednisone (1 mg per kilogram per day) for ...
R W, Beck   +9 more
openaire   +1 more source

Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.

Ophthalmology, 1993
Visual function in the fellow eye at the onset of unilateral optic neuritis has not been systematically evaluated. The authors prospectively determined the prevalence of abnormalities in the fellow eyes of the 448 eligible patients entered into the Optic Neuritis Treatment Trial.All patients underwent testing of visual acuity, contrast sensitivity ...
R W, Beck   +3 more
openaire   +1 more source

The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial.

Transactions of the American Ophthalmological Society, 1996
We sought to characterize the dyschromatopsia of optic neuritis, to determine the type and severity of color defect present and its relation to central vision and spatial acuity, to examine changes in this dyschromatopsia over time, and to determine the applicability of Köllner's rule to patients with optic neuritis.We analyzed the raw data on color ...
openaire   +1 more source

The Optic Neuritis Treatment Trial

Archives of Ophthalmology, 1992
openaire   +1 more source

Optic Neuritis Treatment Trial

Journal of Neuro-Ophthalmology, 1995
openaire   +1 more source

Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.

Archives of ophthalmology (Chicago, Ill. : 1960), 1997
To assess the 5-year visual course, including the incidence of recurrent optic neuritis, in 454 patients enrolled in the Optic Neuritis Treatment Trial.Five-year follow-up vision testing, which included measures of visual acuity, contrast sensitivity, visual field, and color vision, was completed for 397 (87%) of the 454 patients.Visual function test ...
openaire   +1 more source

Home - About - Disclaimer - Privacy